# Novartis Cholesterol Drug Pelacarsen Fails to Reduce Heart Attack Risk in Trial Experimental therapy successfully lowered genetic lipoprotein(a) levels but showed no clinical cardiovascular benefit. - **Source:** [NBC News – Health](https://www.nbcnews.com/health) - **Published:** 2026-11-07 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/e76032cc-972a-4963-915b-24cb6c4a646a ## Clinical Trial Unexpected Failure Novartis recently reported that its experimental drug, pelacarsen, failed to prevent heart attacks or strokes in a major clinical trial. Despite successfully targeting lipoprotein(a), a genetic cholesterol risk factor, the treatment showed zero measurable impact on cardiovascular deaths or urgent medical procedures. Researchers described the findings as a massive disappointment. ## Targeting Genetic Lipoprotein(a) Pelacarsen was designed to address lipoprotein(a), a lethal form of cholesterol that causes plaque buildup and blood clots. Unlike standard LDL cholesterol, this particle is entirely genetic, meaning diet and exercise have no effect on levels. Approximately one in five Americans carries high levels of this specific, stealthy risk factor. ## Horizon Trial Study Scope The Horizon trial involved 8,322 participants, all of whom had previously experienced a heart attack, stroke, or other cardiac event within the last decade. Conducted across nearly 800 global sites, the study followed these patients for an average of five years to determine if lowering lipoprotein(a) could improve long-term health outcomes. ## Significant Reduction Without Benefit The drug demonstrated high efficacy in its primary mechanism, reducing lipoprotein(a) levels by 78% compared to a 13% reduction in the placebo group. However, this substantial biochemical change failed to translate into improved cardiovascular health. The data showed no difference in major events between those receiving the drug and the placebo. ## Expert Reaction and Surprise Leading cardiologists expressed profound shock at the neutral results, as many had anticipated a clear clinical benefit. Dr. Steven Nissen of the Cleveland Clinic noted that the scientific community widely believed lowering these levels would reduce major events. The findings have now forced experts to re-evaluate their understanding of cholesterol. ## Potential Timing and Limitations Researchers are currently theorizing why the therapy failed to produce the expected results. One prominent hypothesis suggests the intervention may have been administered too late in the patients' lives. With an average participant age of 60, the underlying arterial damage might have already been too advanced for the drug to reverse. ## Comparison to Established Markers The results stand in stark contrast to other cardiovascular treatments where lowering LDL cholesterol or blood pressure provides clear, proven benefits. Because this trial showed no evidence that greater reduction led to better outcomes, it challenges the long-held assumption that lipoprotein(a) levels alone dictate the risk of future cardiac events. ## Future of Preventive Cardiology This failure represents a significant setback for preventive cardiology and the development of novel therapies targeting genetic markers. As the medical community digests the data published in the New England Journal of Medicine, future research must determine if earlier intervention is necessary or if other biological mechanisms are at play. ## Sources covering this story - [NBC News – Health — Novartis Cholesterol Drug Fails to Prevent Heart Attacks in Clinical Trial](https://www.nbcnews.com/health/health-news/cholesterol-drug-lipoprotein-a-fails-heart-attacks-stroke-trial-rcna607237) - [STAT — Novartis Cardiovascular Drug Fails to Improve Patient Outcomes in Phase 3](https://www.statnews.com/2026/11/07/aha-conference-news-novartis-lp-a-pelacarsen-heart-disease-trial-mystery/?utm_campaign=rss) --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._